Rezulin is a drug owned by Pfizer Pharmaceuticals Ltd. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 13, 2017. Details of Rezulin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5859037 | Sulfonylurea-glitazone combinations for diabetes |
Nov, 2017
(7 years ago) |
Expired
|
| US6011049 | Combinations for diabetes |
Nov, 2017
(7 years ago) |
Expired
|
| US5602133 | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
Sep, 2013
(11 years ago) |
Expired
|
| US6046202 | Use of thiazolidinedione derivatives in the treatment of insulin resistance |
Sep, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Rezulin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rezulin's family patents as well as insights into ongoing legal events on those patents.
Rezulin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rezulin's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 13, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rezulin Generics:
There are no approved generic versions for Rezulin as of now.
Alternative Brands for Rezulin
Rezulin which is used for treating insulin resistance and managing type II diabetes, including gestational diabetes., has several other brand drugs in the same treatment category and using the same active ingredient (Troglitazone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Sankyo |
| |||
About Rezulin
Rezulin is a drug owned by Pfizer Pharmaceuticals Ltd. It is used for treating insulin resistance and managing type II diabetes, including gestational diabetes. Rezulin uses Troglitazone as an active ingredient. Rezulin was launched by Pfizer Pharms in 1997.
Approval Date:
Rezulin was approved by FDA for market use on 29 January, 1997.
Active Ingredient:
Rezulin uses Troglitazone as the active ingredient. Check out other Drugs and Companies using Troglitazone ingredient
Treatment:
Rezulin is used for treating insulin resistance and managing type II diabetes, including gestational diabetes.
Dosage:
Rezulin is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 400MG | TABLET | Discontinued | ORAL |
| 200MG | TABLET | Discontinued | ORAL |
| 300MG | TABLET | Discontinued | ORAL |